ATE405679T1 - Synthetische humane neutralisierende monoklonale antikörper gegen hiv - Google Patents

Synthetische humane neutralisierende monoklonale antikörper gegen hiv

Info

Publication number
ATE405679T1
ATE405679T1 AT94931922T AT94931922T ATE405679T1 AT E405679 T1 ATE405679 T1 AT E405679T1 AT 94931922 T AT94931922 T AT 94931922T AT 94931922 T AT94931922 T AT 94931922T AT E405679 T1 ATE405679 T1 AT E405679T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
antibodies against
synthetic human
against hiv
neutralizing monoclonal
Prior art date
Application number
AT94931922T
Other languages
English (en)
Inventor
Carlos F Barbas
Dennis R Burton
Richard A Lerner
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE405679T1 publication Critical patent/ATE405679T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT94931922T 1993-10-19 1994-10-19 Synthetische humane neutralisierende monoklonale antikörper gegen hiv ATE405679T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13940993A 1993-10-19 1993-10-19
US23361994A 1994-04-26 1994-04-26
US30884194A 1994-09-19 1994-09-19

Publications (1)

Publication Number Publication Date
ATE405679T1 true ATE405679T1 (de) 2008-09-15

Family

ID=27385329

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94931922T ATE405679T1 (de) 1993-10-19 1994-10-19 Synthetische humane neutralisierende monoklonale antikörper gegen hiv

Country Status (8)

Country Link
US (2) US6261558B1 (de)
EP (1) EP0724651B1 (de)
JP (2) JPH09505466A (de)
AT (1) ATE405679T1 (de)
AU (1) AU8083594A (de)
CA (1) CA2174532A1 (de)
DE (1) DE69435126D1 (de)
WO (1) WO1995011317A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187247A1 (en) * 1992-09-30 2003-10-02 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE122004000004I1 (de) 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
WO1998039482A1 (en) * 1997-03-07 1998-09-11 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
US7763258B2 (en) * 1997-05-20 2010-07-27 The Trustees Of The University Of Pennsylvania Virus-like particles (VLPs) comprising heterologous multiple membrane spanning proteins
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US20070111259A1 (en) * 1999-10-02 2007-05-17 Medarex, Inc. Human antibodies
US7135287B1 (en) 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
CA2436671C (en) * 2000-12-05 2015-02-03 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
WO2002046434A2 (en) * 2000-12-08 2002-06-13 Alexion Pharmaceuticals, Inc. Plasmid vectors
WO2002046436A2 (en) * 2000-12-08 2002-06-13 Alexion Pharmaceuticals, Inc. Plasmid vectors
EP1390489B1 (de) 2001-04-27 2006-02-01 Alexion Pharmaceuticals, Inc. Phagemidvektoren
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
DE60237704D1 (de) * 2001-10-16 2010-10-28 Government Of The Us Secretary Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
GB0202206D0 (en) * 2002-01-31 2002-03-20 Bioinvent Int Ab Method of making libraries of anti-ligands
CA2485120C (en) * 2002-05-06 2013-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
EP1554392A4 (de) * 2002-05-06 2007-08-08 Us Gov Health & Human Serv Identifizierung neuer neutralisierender menschlicher monoklonaler antikörper mit breiter kreuzreaktivität unter verwendung eines sequentiellen antigen-panning von phagen-display-bibliotheken
US20050014230A1 (en) * 2003-07-16 2005-01-20 Ccl Holding Co., Ltd. Preparation of fully human antibodies
EP1677825A4 (de) * 2003-09-19 2008-11-05 Scripps Research Inst An eine breit neutralisierende anti-hiv-antikörper-struktur des 4e10 fab fragmentkomplexes bindendes peptid, seine verwendungen und zusammensetzungen daraus
US20110124842A1 (en) * 2003-09-19 2011-05-26 Brunel Florence M Peptide that binds to a broadly neutralizing anti-HIV antibody-structure of 4E10 Fab fragment complex, uses thereof, compositions therefrom
US7750123B2 (en) * 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof
US20080038280A1 (en) * 2004-10-14 2008-02-14 Government Of The United States Of America A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines
CA2585574A1 (en) * 2004-10-29 2006-05-11 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
US8026477B2 (en) * 2006-03-03 2011-09-27 Ionsense, Inc. Sampling system for use with surface ionization spectroscopy
EP2328920A2 (de) * 2008-08-25 2011-06-08 Amplimmune, Inc. Zielgerichtete, kostimulierende polypeptide und anwendungsverfahren zur behandlung von krebs
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
TWI769982B (zh) 2015-06-24 2022-07-11 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之抗人類運鐵蛋白受體抗體
WO2018021012A1 (ja) * 2016-07-28 2018-02-01 株式会社カネカ 抗体断片の製造方法
CN109983031B (zh) 2016-12-26 2022-11-25 Jcr制药股份有限公司 通过血脑屏障的新的抗人转铁蛋白受体抗体
KR102573622B1 (ko) 2016-12-26 2023-08-31 제이씨알 파마 가부시키가이샤 Bdnf를 포함하는 융합 단백질
US20210038739A1 (en) 2018-02-05 2021-02-11 Jcr Pharmaceuticals Co., Ltd. Method for Delivering Drug to Muscle
BR112021021261A2 (pt) * 2019-04-22 2021-12-21 Ddbio Co Ltd Shang Hai Método para produzir uma biblioteca de fagos que exibe um anticorpo ou fragmento de anticorpo, biblioteca de fagos e método para selecionar um anticorpo ou fragmento de anticorpo
CN118440204A (zh) 2019-12-27 2024-08-06 凯奥目生物科学株式会社 抗cdcp1抗体
JPWO2022049867A1 (de) 2020-09-02 2022-03-10
AU2022390281A1 (en) 2021-11-19 2024-06-13 Jcr Pharmaceuticals Co., Ltd. Peptide having affinity for human transferrin receptor
WO2024024565A1 (ja) 2022-07-28 2024-02-01 国立大学法人 東京大学 ニューロトリミンの機能阻害剤
AU2024217434A1 (en) 2023-02-07 2025-08-07 Jcr Pharmaceuticals Co., Ltd. Human transferrin receptor affinity peptide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AP237A (en) * 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
AU8228791A (en) * 1990-06-15 1992-01-07 New York University Heterohybridomas producing human monoclonal antibodies to hiv-1
AU2784792A (en) * 1991-10-15 1993-05-21 New York University Human monoclonal antibodies to the cd4-binding domain of hiv, uses thereof and synergistic neutralization of hiv

Also Published As

Publication number Publication date
AU8083594A (en) 1995-05-08
DE69435126D1 (de) 2008-10-02
EP0724651B1 (de) 2008-08-20
US6261558B1 (en) 2001-07-17
US6395275B1 (en) 2002-05-28
EP0724651A1 (de) 1996-08-07
JPH09505466A (ja) 1997-06-03
EP0724651A4 (de) 1998-11-04
WO1995011317A1 (en) 1995-04-27
CA2174532A1 (en) 1995-04-27
JP2005198654A (ja) 2005-07-28

Similar Documents

Publication Publication Date Title
ATE405679T1 (de) Synthetische humane neutralisierende monoklonale antikörper gegen hiv
NO951212L (no) Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus
NO970221L (no) Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus
CA2144043A1 (en) Human neutralizing monoclonal antibodies to respiratory syncytial virus
EP0528931A4 (en) Humanized chimeric anti-icam-1 antibodies, methods of preparation and use
ID23374A (id) Halogenopirimidin
DK0552296T3 (da) Monoklonale antistoffer fra mus
ATE309365T1 (de) Hiv-1 der gruppe 0, entsprechende fragmente dieses virus,sowie deren anwendungen
ATE335835T1 (de) Antikörper gegen einen komplex aus cd4 und einer chemokinrezeptordomäne, sowie deren verwendung gegen hiv infektionen
DK0802924T3 (da) Lægemiddel til forlænget immunsuppression og eliminering af tumorceller
CA2008817A1 (en) M-csf monoclonal antibodies that recognize a neutralizing conformational epitope
AU4959193A (en) High affinity, strongly neutralizing monoclonal antibodies against the CD-4 binding site of GP120 of human immunodeficiency virus
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
ATE132502T1 (de) Peptide, die epitope auf r-ifn-beta repräsentieren, antikörper dagegen, und ihre anwendung
DE69010897D1 (de) Verwendung von monoklonalen Antikörpern gegen B2-Mikroglobulin.
ATE309371T1 (de) Protein mit dnase-aktivität
DE69617255D1 (de) Durch hla-b44 moleküle präsentierte tumor-abstossungsantigene und ihre verwendung
DE68926454D1 (de) Gegen hiv 1 gp48 spezifische antikörper
EP0243174A3 (de) Monoklonale Antikörper gegen Pseudomonas aeruginosa Exoenzym S, ihre Herstellung und Verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties